

10/502431

DT Sec'd PCT/PTO 22 JUL 2004

AC/TMH:gte 07/22/04
PATENT

EXPRESS MAIL LABEL NO. EV514604067US
Date of Deposit: July 22, 2004
Attorney Reference Number 4239-64141-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Harris et al.

Application No. _____

Filed: Herewith

Confirmation No. _____

For: NEW TUMOR SUPPRESSOR GENE,
P28ING5

Examiner: _____

Art Unit: _____

Attorney Reference No. 4239-64141-02

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(1)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Since the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). Applicants will provide copies of such patents upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the filing date of a national application. As a result, no fee should be required to file this IDS.

10/502431

Rec'd PCT/PTO 22 JUL 2004

AC/TMH:gte 07/22/04
PATENT


EXPRESS MAIL LABEL NO. EV514604067US
Date of Deposit: July 22, 2004
Attorney Reference Number 4239-64141-02

However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, Deposit Account No. 02-4550 authority is provided on the enclosed transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Anne Carlson, Ph.D.
Registration No. 47,472

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

JT12 Rec'd PCT/PTO 22 JUL 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-64141-02
	Application Number	
	Filed	Herewith
	First Named Inventor	Harris
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,965,398	12 Oct 1999	Garkavtsev <i>et al.</i>
		6,066,474	23 May 2000	Marcu
		6,117,633	12 Sep 2000	Garkavtsev <i>et al.</i>
		6,238,918	29 May 2001	Garkavtsev <i>et al.</i>
		2004/0058379	25 March 2004	Harris <i>et al.</i>
		2004/0115747	17 June 2004	Harris <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/36476	25 May 2001	Rigel Pharmaceuticals, Inc.
		WIPO	WO 01/47959	5 July 2001	Jager <i>et al.</i>

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Garkavtsev <i>et al.</i> , "Suppression of the Novel Growth Inhibitor p33 ^{ING1} Promotes Neoplastic Transformation," <i>Nature Genetics</i> 14:415-420, 1996
		Garkavtsev <i>et al.</i> , "Extension of the Replicative Life Span of Human Diploid Fibroblasts by Inhibition of the p33 ^{ING1} Candidate Tumor Suppressor," <i>Mol. Cell Biol.</i> 17(4):2014-2019, April 1997
		Garkavtsev <i>et al.</i> , "The Candidate Tumour Suppressor p33 ^{ING1} Cooperates with p53 in Cell Growth Control," <i>Nature</i> 391:295-298, 1998

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-64141-02
		Application Number	10/502431
		Filed	Herewith
		First Named Inventor	Harris
		Art Unit	
		Examiner Name	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
		Loewith <i>et al.</i> , "Three Yeast Proteins Related to the Human Candidate Tumor Suppressor p33 ^{ING1} Are Associated with Histone Acetyltransferase Activities," <i>Mol. Cell Biol.</i> 20(11):3807-3816, June 2000	
		Zeremski <i>et al.</i> , "Structure and Regulation of the Mouse <i>ing1</i> Gene," <i>J. Biol. Chem</i> 274(45):32172-32181, 1999	
		GenBank Accession No. AAB82387, 25 October 1997, 2 pages	
		GenBank Accession No. AAD48585, 12 August 1999, 1 page	
		GenBank Accession No. AF110645, 12 August 1999, 2 pages	
		GenBank Accession No. AF189286, 30 January 2002, 2 pages	
		GenBank Accession No. AX147962, 8 June 2001, 1 page	
		GenBank Accession No. BC005370, 12 July 2001, 2 pages	
		GenBank Accession No. BG170225, 6 February 2001, 2 pages	
		GenBank Accession No. BG753113, 15 May 2001, 2 pages	
		GenBank Accession No. NM_032329, 19 May 2001, 2 pages	
		GenBank Accession No. NP_115705.1, 19 May 2001, 1 page	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	